Recursion Pharmaceuticals Overview

  • Founded
  • 2013

Founded
  • Status
  • Public

  • Employees
  • 500

Employees
  • Stock Symbol
  • RXRX

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $7.26

  • (As of Monday Closing)

Recursion Pharmaceuticals General Information

Description

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 41 South Rio Grande Street
  • Salt Lake City, UT 84101
  • United States
+1 (385) 000-0000

Recursion Pharmaceuticals Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recursion Pharmaceuticals Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.26 $7.41 $4.92 - $14.18 $1.42B 191M 989K -$1.36

Recursion Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 1,059,019 1,059,019 2,321,561
Revenue 39,681 39,681 10,000 3,413
EBITDA (233,919) (233,919) (175,195) (82,039)
Net Income (239,476) (239,476) (186,479) (87,006)
Total Assets 701,288 701,288 610,345 298,585
Total Debt 51,005 51,005 11,478 15,662
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recursion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technolog
Biotechnology
Salt Lake City, UT
500 As of 2022
00.000
0.000 0000-00-00
000000000 00.000

000000

r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000000000000
Branford, CT

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000 000000000
Nottingham, United Kingdom
000 As of 0000
000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recursion Pharmaceuticals Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioXcel Corporation Branford, CT
000000000 00000000 Private Equity-Backed Nottingham, United Kingdom 000 000000000
0000000 Venture Capital-Backed Toronto, Canada 00 000.00 00000 000.00
000000000000 Formerly PE-Backed London, United Kingdom 000 00000 000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000&0 00000
You’re viewing 5 of 26 competitors. Get the full list »

Recursion Pharmaceuticals Patents

Recursion Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220397565-A1 Methods of screening and related systems Pending 10-Jun-2021 00000000000
US-20220380323-A1 Heterocyclic compounds and related methods Pending 02-Mar-2021 000000000
US-20220262455-A1 Determining the goodness of a biological vector space Pending 18-Feb-2021 0000000000
US-20220238181-A1 Crispr guide selection Pending 27-Jan-2021 00000000
US-20220162601-A1 High throughput gene editing system and method Pending 23-Nov-2020 C12N9/22 0
To view Recursion Pharmaceuticals’s complete patent history, request access »

Recursion Pharmaceuticals Executive Team (25)

Name Title Board Seat Contact Info
Christopher Gibson Ph.D Chief Executive Officer & Founder
Tina Larson Chief Operating Officer, Operations & President
Michael Secora Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ben Mabey Chief Technology Officer
Ben Sukow Director of Engineering
You’re viewing 5 of 25 executive team members. Get the full list »

Recursion Pharmaceuticals Board Members (14)

Name Representing Role Since
Alaa Halawa Mubadala Investment Company Board Observer 000 0000
Blake Borgeson Ph.D Recursion Pharmaceuticals Founder & Board Member 000 0000
Dean Li Ph.D Recursion Pharmaceuticals Co-Founder & Board Member 000 0000
James Hardiman DCVC Board Observer 000 0000
Lee Cooper JD Leaps by Bayer Board Observer 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Recursion Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recursion Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 22-Jun-2021 00000 0000 0000 Biotechnology
Vium 28-Jul-2020 Merger/Acquisition Discovery Tools (Healthcare) 000000000
To view Recursion Pharmaceuticals’s complete investments and acquisitions history, request access »

Recursion Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
0000 Discovery Tools (Healthcare) San Mateo, CA 0000
To view Recursion Pharmaceuticals’s complete subsidiaries history, request access »

Recursion Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated October, 30, 2022

22.1 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,231

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 899

Rank

00.0

Percentile

Biotechnology

Subindustry

00 of 401

Rank

0.00

Percentile

To view Recursion Pharmaceuticals’s complete esg history, request access »